Targeting PFKFB3 Metabolic Gatekeeping of β-Cell Dysfunctional States Enables Durable Glucose Tolerance in Type 2 Diabetes
Kavit Raval, Erwin Ilegems, Alexandra C. Title, Emme Fishburn, Gurprit Bhardwaj, Olivier Mirguet, Paul D. Ratcliffe, Oppel B.W. Greeff, Abraham van Wyk, Slavica Tudzarova
This study shows that inhibiting PFKFB3 improves glucose tolerance in type 2 diabetes by restoring β-cell function and reducing dysfunctional states, with effects lasting after treatment stops.
bioRxiv · Sep 22, 2026 · PreprintCell Biology